KR102585048B1 - Jak1 선택적 억제제 - Google Patents
Jak1 선택적 억제제 Download PDFInfo
- Publication number
- KR102585048B1 KR102585048B1 KR1020197023855A KR20197023855A KR102585048B1 KR 102585048 B1 KR102585048 B1 KR 102585048B1 KR 1020197023855 A KR1020197023855 A KR 1020197023855A KR 20197023855 A KR20197023855 A KR 20197023855A KR 102585048 B1 KR102585048 B1 KR 102585048B1
- Authority
- KR
- South Korea
- Prior art keywords
- fluoro
- indol
- methylsulfonyl
- amino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237032917A KR102659213B1 (ko) | 2017-01-17 | 2018-01-16 | Jak1 선택적 억제제 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 | |
| US62/447,057 | 2017-01-17 | ||
| PCT/EP2018/051038 WO2018134213A1 (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237032917A Division KR102659213B1 (ko) | 2017-01-17 | 2018-01-16 | Jak1 선택적 억제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190104215A KR20190104215A (ko) | 2019-09-06 |
| KR102585048B1 true KR102585048B1 (ko) | 2023-10-05 |
Family
ID=61024756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197023855A Active KR102585048B1 (ko) | 2017-01-17 | 2018-01-16 | Jak1 선택적 억제제 |
| KR1020237032917A Active KR102659213B1 (ko) | 2017-01-17 | 2018-01-16 | Jak1 선택적 억제제 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237032917A Active KR102659213B1 (ko) | 2017-01-17 | 2018-01-16 | Jak1 선택적 억제제 |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| PT3514153T (pt) | 2017-01-26 | 2021-09-22 | Hanmi Pharm Ind Co Ltd | Composto de pirimidina e utilização farmacêutica do mesmo |
| EP3823964A1 (en) * | 2018-07-18 | 2021-05-26 | Astrazeneca AB | A xinafoate salt of a jak inhibiting compound |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CN112823159B (zh) * | 2018-09-21 | 2024-03-01 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
| PE20212153A1 (es) | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| CA3134174A1 (en) * | 2019-04-19 | 2020-10-22 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Jak1 selective kinase inhibitor |
| KR20210002015A (ko) | 2019-06-27 | 2021-01-06 | 한미약품 주식회사 | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| EP4132920B1 (en) * | 2020-04-09 | 2025-08-13 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| WO2022111499A1 (zh) * | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| JP2024509795A (ja) * | 2021-02-26 | 2024-03-05 | タイラ・バイオサイエンシーズ・インコーポレイテッド | アミノピリミジン化合物及びその使用方法 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| EP4648776A1 (en) * | 2023-01-11 | 2025-11-19 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
| CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
| TW202438061A (zh) * | 2023-03-16 | 2024-10-01 | 美商英塞特公司 | 用於治療氣喘之ｊａｋ１路徑抑制劑 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008515986A (ja) | 2004-10-13 | 2008-05-15 | ワイス | Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2017050938A1 (en) | 2015-09-25 | 2017-03-30 | Astrazeneca Ab | Compounds and methods for inhibiting jak |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| JP2010518025A (ja) | 2007-02-05 | 2010-05-27 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール |
| WO2009045700A2 (en) | 2007-10-05 | 2009-04-09 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| PH12015502575A1 (en) | 2010-03-10 | 2017-04-24 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| JP5822934B2 (ja) * | 2010-09-15 | 2015-11-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アザベンゾチアゾール化合物、組成物及び使用方法 |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
-
2018
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active Active
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active Active
- 2018-01-16 NZ NZ756069A patent/NZ756069A/en unknown
- 2018-01-16 MX MX2019008435A patent/MX390625B/es unknown
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en not_active Ceased
- 2018-01-16 SM SM20230051T patent/SMT202300051T1/it unknown
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 CN CN202211243959.9A patent/CN115925693B/zh active Active
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 PH PH1/2019/501639A patent/PH12019501639B1/en unknown
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 MY MYPI2019004083A patent/MY199735A/en unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-15 MX MX2022002976A patent/MX2022002976A/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP7626819B2/ja active Active
- 2023-12-13 US US18/538,067 patent/US12473272B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008515986A (ja) | 2004-10-13 | 2008-05-15 | ワイス | Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2017050938A1 (en) | 2015-09-25 | 2017-03-30 | Astrazeneca Ab | Compounds and methods for inhibiting jak |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102585048B1 (ko) | Jak1 선택적 억제제 | |
| CN115703761A (zh) | 作为wwp1抑制剂的化合物及其应用 | |
| JP2024527623A (ja) | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| WO2016140501A1 (en) | Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors | |
| WO2017175185A1 (en) | Heteroaryl butanoic acid derivatives as lta4h inhibitors | |
| HK40098388A (en) | Jak1 selective inhibitors | |
| CA3179325A1 (en) | Kinase inhibitors and uses thereof | |
| HK40017725A (en) | Jak1 selective inhibitors | |
| HK40017725B (en) | Jak1 selective inhibitors | |
| BR112019014526B1 (pt) | Composto, composição farmacêutica e uso de um composto no tratamento de uma disfunção relacionada com jak1 | |
| HK40016478B (en) | Jak1 selective inhibitors | |
| HK40016478A (en) | Jak1 selective inhibitors | |
| WO2025217330A1 (en) | Cysteine covalent modifiers of akt1 and uses thereof | |
| EP3081556A1 (en) | Amide compound and pharmaceutical comprising same | |
| JP2025540298A (ja) | Ｈｄａｃ阻害剤およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190814 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210111 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230329 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230628 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20230925 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230926 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230926 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |